- Home
- XMAX vs DCTH Comparison
XMAX vs DCTH Comparison
Compare XMAX & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XMAX | DCTH |
|---|---|---|
| Founded | 2003 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.8M | 578.4M |
| IPO Year | 2009 | 2015 |
Fundamental Metrics
Financial Performance| Metric | XMAX | DCTH |
|---|---|---|
| Price | $8.44 | $14.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | ★ 680.8K | 248.2K |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 88.51 | ★ 107.53 |
| EPS | ★ 0.62 | 0.04 |
| Revenue | ★ $12,744,871.00 | N/A |
| Revenue This Year | N/A | $24.61 |
| Revenue Next Year | N/A | $24.27 |
| P/E Ratio | ★ $13.54 | $362.50 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.06 | $8.12 |
| 52 Week High | $9.40 | $17.42 |
Technical Indicators
Market Signals| Indicator | XMAX | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 44.38 | 45.82 |
| Support Level | $8.33 | $14.52 |
| Resistance Level | $8.97 | $16.51 |
| Average True Range (ATR) | 0.30 | 0.48 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 37.70 | 45.76 |
Price Performance
Historical ComparisonAbout XMAX XMAX Inc. Common Stock
XMax Inc is a designer and lifestyle furniture company. The company is a designer and distributor of contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. The company plans expansion into artificial intelligence (AI) while continuing to operate and develop its existing furniture business.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.